Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.50 |
| ▸ | DRD2 | P14416 | 5/20 | 0.50 |
| ▸ | DRD3 | P35462 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525342 | 0.93 | DRD4 (0.56) | DRD4DRD2DRD3HTR1ACHRM5 | |
| Oxalic Acid SCHEMBL7520209 | 0.91 | DRD2 (0.49) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL7528961 | 0.85 | DRD4 (0.68) | DRD4DRD2DRD3HTR1ACHRM5 | |
| SCHEMBL7531148 | 0.83 | DRD2 (0.55) | DRD4DRD2DRD3TMEM97SIGMAR1 | |
| SCHEMBL12208585 | 0.78 | CTNNB1 (0.45) | ALDH1A1MAPTKMT2A | |
| SCHEMBL7518794 | 0.78 | DRD4 (0.78) | DRD4DRD2DRD3HTR1ACHRM5 | |
| Oxalic Acid SCHEMBL7532474 | 0.76 | DRD2 (0.67) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL7523502 | 0.76 | DRD2 (0.86) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL7526570 | 0.75 | DRD2 (0.60) | DRD4DRD2DRD3HTR1ASIGMAR1 | |
| Oxalic Acid SCHEMBL7523549 | 0.73 | DRD4 (0.63) | DRD4DRD2DRD3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486164-B2 | USED FOR TREATMENT OF NEUROPSYCHOLOGICAL DISORDERS INCLUDING SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE, PARKINSON-LIKE MOTOR DISORDERS AND MOTION DISORDERS NEUROLEPTIC AGENTS. | NEUROGEN CORPORATION | 2002-11-26 | — | — | US | disclosed |
| US-20020099056-A1 | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkypiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-07-25 | — | — | US | disclosed |
| US-6333329-B2 | USEFUL FOR TREATMENT AND/OR PREVENTION OF NEUROPSYCHOLOGICAL DISORDERS INCLUDING SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, DRUG ABUSE, PARKINSON-LIKE MOTOR DISORDERS AND MOTION DISORDERS | NEUROGEN CORPORATION | 2001-12-25 | — | — | US | disclosed |
| US-20010005753-A1 | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2001-06-28 | — | — | US | disclosed |
| EP-1091949-A2 | 6-(4-ARYLALKYLPIPERAZIN-1-YL)BENZODIOXANE AND 6-(4-ARYLALKYLPIPERAZIN-1-YL)CHROMANE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-04-18 | — | — | EP | disclosed |
| US-6177566-B1 | TREATMENT AND/OR PREVENTION OF NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-01-23 | — | — | US | disclosed |
| WO-2000000489-A2 | 6-(4-ARYLALKYLPIPERAZIN-1-YL)BENZODIOXANE AND 6-(4-ARYLALKYLPIPERAZIN-1-YL)CHROMANE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005753-A1 | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands | CHRNA6, HTR2C, HTR3C | DRD4 28/4885DRD2 9/4885DRD3 22/4885 |
| US-20020099056-A1 | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkypiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands | CHRNA6, HTR3C, HTR2C | DRD4 28/4885DRD2 7/4885DRD3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.